Mutala Linda Bilonda, Deleine Cécile, Karakachoff Matilde, Dansette Delphine, Ducoin Kathleen, Oger Romain, Rousseau Olivia, Podevin Juliette, Duchalais Emilie, Fourquier Pierre, Thomas Wassila El Alami, Gourraud Pierre-Antoine, Bennouna Jaafar, Brochier Camille, Gervois Nadine, Bossard Céline, Jarry Anne
Institut Roche, 92100 Boulogne-Billancourt, France.
Inserm, CRCINA, Université de Nantes, 44000 Nantes, France.
Cancers (Basel). 2021 Jan 7;13(2):189. doi: 10.3390/cancers13020189.
In colorectal cancer (CRC), a high density of T lymphocytes represents a strong prognostic marker in subtypes of CRC. Optimized immunotherapy strategies to boost this T-cell response are still needed. A good candidate is the inflammasome pathway, an emerging player in cancer immunology that bridges innate and adaptive immunity. Its effector protein caspase-1 matures IL-18 that can promote a T-helper/cytotoxic (Th1/Tc1) response. It is still unknown whether tumor cells from CRC possess a functional caspase-1/IL-18 axis that could modulate the Th1/Tc1 response. We used two independent cohorts of CRC patients to assess IL-18 and caspase-1 expression by tumor cells in relation to the density of TILs and the microsatellite status of CRC. Functional and multiparametric approaches at the protein and mRNA levels were performed on an ex vivo CRC explant culture model. We show that, in the majority of CRCs, tumor cells display an activated and functional caspase-1/IL-18 axis that contributes to drive a Th1/Tc1 response elicited by TILs expressing IL-18Rα. Furthermore, unsupervised clustering identified three clusters of CRCs according to the caspase-1/IL-18/TIL density/interferon gamma (IFNγ) axis and microsatellite status. Together, our results strongly suggest that targeting the caspase-1/IL-18 axis can improve the anti-tumor immune response in subgroups of CRC.
在结直肠癌(CRC)中,高密度的T淋巴细胞是CRC亚型中一个强大的预后标志物。仍需要优化免疫治疗策略来增强这种T细胞反应。一个很好的候选对象是炎性小体途径,它是癌症免疫学中一个新兴的参与者,连接先天免疫和适应性免疫。其效应蛋白半胱天冬酶-1可使白细胞介素-18成熟,后者可促进辅助性T细胞/细胞毒性T细胞(Th1/Tc1)反应。目前尚不清楚CRC的肿瘤细胞是否拥有一个可调节Th1/Tc1反应的功能性半胱天冬酶-1/白细胞介素-18轴。我们使用两个独立的CRC患者队列,评估肿瘤细胞中白细胞介素-18和半胱天冬酶-1的表达与肿瘤浸润淋巴细胞(TILs)密度及CRC微卫星状态的关系。在一个体外CRC外植体培养模型上进行了蛋白质和mRNA水平的功能及多参数分析。我们发现,在大多数CRC中,肿瘤细胞显示出一个激活的且功能性的半胱天冬酶-1/白细胞介素-18轴,该轴有助于驱动由表达白细胞介素-18受体α(IL-18Rα)的TILs引发的Th1/Tc1反应。此外,无监督聚类根据半胱天冬酶-1/白细胞介素-18/TIL密度/干扰素γ(IFNγ)轴和微卫星状态确定了三组CRC。总之,我们的结果强烈表明,靶向半胱天冬酶-1/白细胞介素-18轴可改善CRC亚组中的抗肿瘤免疫反应。